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Abstract
Background: To assess the long term efficacy and tolerability of one or two ultrasound (US)-guided high-intensity
focused ultrasound (HIFU) treatment in patients with breast fibroadenoma (FA).
Methods: Twenty patients with 26 FA were selected for US-guided HIFU. The therapy was performed in one or two
sessions. FA volume was assessed before and followed up to 24 months after the last HIFU. After each treatment,
adverse events were evaluated.
Results: In 19/26 FA (73.1%) one HIFU was performed (group 1), whereas 7/26 FA (26.9%) received second HIFU
(group 2) 6-9 months (median, 7 months) after the first session. In group 1 and 2, FA volume decreased significantly
at 1-month (p < 0.001) and 3-month follow-up (p = 0.005), respectively, and continued to reduce until 24-month
follow-up (p < 0.001 and p = 0.003, respectively). At 24 months, mean volume reduction was 77.32% in group 1 and
90.47% in group 2 (p = 0.025). Mild subcutaneous edema was observed in 4 patients and skin erythema in 3 patients.
Conclusions: US-guided HIFU represents a promising non-invasive method with sustainable FA volume reduction and
patient’s tolerability. Although one treatment is highly efficient, the volume reduction can be increased with second
treatment.
Trial registration: NCT01331954. Registered 07 April 2011.
Keywords: Breast fibroadenoma, High-intensity focused ultrasound (HIFU), Ultrasound (US) guidance, Ablation
techniques, Interventional ultrasonography
Background
Breast fibroadenomas (FA) are the most prevalent be-
nign tumours, accounting for up to 70% of benign breast
lesions [1, 2]. Most frequently, they affect females in the
reproductive period with two peaks of incidence in the
third and in the fifth decade of life. They may also occur
after menopause as a result of hormone replacement
therapy [3, 4]. Although FA, typically consisting of stro-
mal and epithelial cells, usually occurs unilaterally, mul-
tiple lesions in the same breast or bilaterally may arise in
20% of cases [4, 5]. Most patients clinically present with
palpable breast lump, detected during medical examin-
ation or self-examination, or occasionally with breast
pain [2, 6]. Without treatment, a minority of FA de-
crease in size or disappear, more than half of them re-
main unchanged, and some of them significantly
increase [7]. The long-term risk for breast carcinoma in
women with FA has not been established [8, 9] and
therefore, a conservative approach to the treatment seems
to be safe especially in younger patients [5, 10, 11].
However, some patients prefer elimination due to large
size, physical discomfort and anxiety about growth or
malignancy. The widely employed surgical excision may
result in scar formation, breast volume loss and potential
for nipple areolar distortion or displacement [12]. Differ-
ent non-surgical techniques have been reported. Vacuum-
assisted biopsy and cryoablation both demonstrated
excellent efficacy, safety and high level of patients’ satisfac-
tion though being minimally invasive [13–15]. The ther-
moablation procedures such as laser, radiofrequency or
* Correspondence: roussanka_kov@yahoo.com
1Department of Thyroid and Metabolic Bone Disorders, University Hospital of
Endocrinology, Medical University of Sofia, 2, Zdrave Street, 1431 Sofia, Bulgaria
Full list of author information is available at the end of the article
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Kovatcheva et al. Journal of Therapeutic Ultrasound  (2017) 5:1 
DOI 10.1186/s40349-017-0083-1
microwave ablation have been reported, but they are more
frequently applied in breast cancer patients [16–19].
The only non-surgical and non-invasive procedure,
employed until today, is high-intensity focused ultra-
sound (HIFU), where thermal destruction is achieved by
precisely delivered energy to a given area in soft tissue
without interrupting skin integrity. Although this tech-
nique has been applied in the treatment of breast cancer,
prostate tumours, uterine fibroids, liver or renal tu-
mours, the experience in breast FA is limited [20]. More
than a decade ago, magnetic resonance (MR)-guided
HIFU ablation of FA was proposed on the basis of dem-
onstrated feasibility and efficacy in a small group of pa-
tients [21]. Recently, Peek et al. showed 43.5% mean FA
volume reduction 6 months after circumferential ultra-
sound (US)-guided HIFU treatment of 19 patients [22].
A multicentre study of Kovatcheva et al. established that
US-guided HIFU treatment of 51 FA resulted in 72.5%
volume reduction at 1-year follow-up [23]. However,
data on prolonged effectiveness and persistence of vol-
ume reduction are missing.
In this prospective study, our aim was to assess the
long-term treatment efficacy and tolerability of one or two
US-guided HIFU sessions in patients with breast FA.
Methods
Study design
In our single-centre study, performed between May 2011
and April 2015, from 58 females with clinical suspicion of
one or more FA in one or both breasts, 20 symptomatic
patients with 26 FA were selected for treatment with
US-guided HIFU. The study was approved by the local
ethics committee and informed consent was obtained
from all individual participants included in the study.
The eligibility criteria included the age of 18 years or
more; the clinical diagnosis of breast FA based on palpa-
tion, US examination alone for patients < 35 years of age,
and mammography in addition for women older than
35 years with Breast Imaging and Reporting Data System
(BI-RADS) score ≤2; and a histological confirmation
after large-core biopsy using a 16-gauge needle size per-
formed at least two weeks before therapy and verified by
two independent readers. The targeted FA size had to be
larger than 10 mm, without macrocalcifications inducing
a substantial shadowing and situated within the treatable
area, which was 5 to 28 mm from the skin surface. The
intended size of the ablation unit was 9 mm in length
and 1.8–2.5 mm in width and the depth of each ablation
unit was adjusted automatically to be centred with the
antero-posterior diameter of the target. The rib cage had
to be outside the treatment cone or at least 10 mm be-
hind the focal point. Those criteria had to be fulfilled in
treatment conditions, once the breast was immobilized
and eventually compressed. We excluded women who
were pregnant or lactating, those with US suspicions for
malignancy, BI-RADS score > 2 or with microcalcifica-
tions within the lesion. Also those with history of breast
cancer, history of laser or radiation therapy of the tar-
geted breast and those with breast implants were ex-
cluded. Thirty-three patients did not meet the inclusion
criteria for the following reasons: pregnancy (n = 1); un-
confirmed diagnosis of FA (n = 11); FA inaccessibility (n =
21) such as localization partly behind the nipple, close to
the rib cage, outside the treatable area, macrocalcifications
in the lump; 4 patients refused to participate.
At a selection visit prior to HIFU ablation, body mass
index (BMI) was calculated according to the formula:
weight/height2 (kg/m2) and US characteristics of FA were
evaluated. After the first HIFU, follow-up visits with US
assessment of FA were performed at 1, 3 and 6 months.
At 6-month follow-up, if FA volume reduced for less
than 50% or its absolute volume exceeded 1.5 ml, a sec-
ond HIFU ablation was performed and all patients were
followed-up at 12 and 24 months after the last treat-
ment. Comparison of FA characteristics was conducted
on the basis of the number of treatment procedures.
US evaluation
US evaluation of the targeted FA was performed using
an 8-MHz linear probe and a real-time color Doppler
US system (Aloka, Prosound Alpha 7, Tokyo, Japan).
The first dimension (d1) was recorded parallel to the skin
in radial position to the nipple. The second dimension
(d2) was measured orthogonal to d1, and the third dimen-
sion (d3) was measured in anteroposterior direction. The
FA volume was calculated by the ellipsoid model (d1 · d2 ·
d3 · π/6). Volume reduction (%) was calculated as: ([basal
volume – final volume] · 100)/basal volume. Before the
treatment, the intranodular color flow Doppler (CFD) pat-
tern was evaluated as follows: pattern 0, absence of flow;
pattern I, presence of flow with patchy, uneven distribu-
tion; pattern II, clearly increased flow with patchy distri-
bution; pattern III, marked increase in blood flow with
diffuse homogeneous distribution [24]. US-guided large-
core biopsy was carried out in each patient and histo-
logical analysis was performed by two independent readers
to prove the benign nature of the targeted FA.
HIFU intervention
HIFU treatment was conducted with a real-time US-
guided HIFU system (EchoPulse, Theraclion, Paris,
France), described in details previously [23]. The ma-
chine consists of a corpus with energy generator, a treat-
ment head and a touch screen interface enabling a
procedure planning and monitoring. The treatment head
consists of an integrated 7.5 MHz linear array transducer
for imaging, a 3 MHz spherical transducer (diameter
of 38 or 56 mm and focal region of 0.5x1.0x2.5 mm)
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to generate HIFU and a cooling system to prevent
skin burn.
The treatment was performed on an outpatient basis
by a single physician (R.K.) with 7 years practice in US-
guided HIFU therapy. The patient was placed in a lateral
position to reduce the respiratory movements and the
breast was supported by a special immobilization system
(SenoPad, Theraclion, Paris, France), consisting in an
adaptable plate with a silicon pad, a pressure plate and 2
articulated arms designed to fix the breast during the
procedure (Fig. 1). Conscious intravenous analgesia was
administered. The physician positioned the treatment
head facing the targeted part of the breast and outlined
the FA in two axes on the touch screen interface. Once
the planning was finished, the treatment started with
consecutive repeated HIFU pulses and cooling pauses with
duration of 6 s and 54 s, respectively. The acoustic output
power was 60 W and the intensity was 25 000 W/cm2.
The treatment head moved automatically to cover the
whole FA volume. The physician controlled the procedure
and adjusted the applied energy to obtain the desired tis-
sue reaction, characterized by hyperechoic marks as a sign
of tissue damage [25]. When hyperechoic marks did not
occur at maximal admissible energy, the treatment was
continued at the lower energy level to avoid thermal dam-
age of surrounding tissues. Treatment duration consisted
of sonication, cooling and repositioning. During therapy,
the patient’s vital parameters were monitored. In case of
intolerant pain patients were asked to make a sign, in
order to receive additional analgesics and the pause before
the next pulse was extended with 30 to 60 s.
At the end of the HIFU procedure, pain related to the
treatment was subjectively rated using a 0–100 mm
visual analogue scale (VAS) and adverse events were
assessed. After the 6-month follow-up, the patients
completed a satisfaction questionnaire evaluating
symptoms and cosmetic improvement with a 4-grade
scale (1 – no, 2 – low, 3 – high, 4 – complete satisfaction).
Data analysis
Data analysis was carried out using the Statistica soft-
ware version 7.1 (StatSoft, Tulsa, OK, USA) and p < 0.05
was considered significant. Data are presented as
mean ± standard deviation (SD) or median and range,
as appropriate according to the distribution. To com-
pare two groups, we applied the Student’s two-tailed
t-test or Mann-Whitney U-test for continuous variables
and the Chi-square for categorical variables. Comparisons
of multiple variables were performed using ANOVA
test, whereas for the follow-up comparison of longitu-
dinally recorded data repeated measures ANOVA test
was used. Correlations were calculated with the Pearson
correlation test.
Results
Patient and FA characteristics
The mean age of 20 patients was 29.0 ± 10.2 years, 7/20
(35%) were previously operated for FA of the same
breast and 7/20 (35%) had more than one FA. Nineteen
of 26 FA (73.1%) were treated with one HIFU session
(group 1). In 7/26 FA (26.9%) second HIFU ablation was
performed (group 2) between 6 and 9 months (median
7 months) after the first session. FA in the group 2 were
significantly larger at baseline, otherwise no significant
differences in FA characteristics were observed between
the two groups (Table 1).
During the first HIFU session, the treated volume,
total applied energy, treatment duration and the number
of treated sites were significantly higher in group 2 than
Fig. 1 Breast support and immobilization system SenoPad
(Theraclion, Paris, France)
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in group 1. The percentage of the treated volume was
significantly lower in group 2, whereas the energy per
treated volume and the percentage of hyperechoic marks
did not differ between both groups (Table 2). During the
second HIFU session, the treated volume and total ap-
plied energy in group 2 were still larger compared with
the baseline values in group 1, whereas other parameters
did not differ significantly (Table 2).
FA volume reduction
In group 1, FA volume decreased significantly as soon as
at 1-month follow-up (median 1.44 mL, range 0.21–
5.18 mL, p < 0.001 compared with the initial value), and
continued to reduce until the 24-month visit (median
0.35 mL, range 0.06–1.21 mL; p < 0.001 compared with
the initial value) (Fig. 2). Illustration of FA treated with
one HIFU session is shown in Fig. 3. In group 2, a sig-
nificant FA shrinkage was observed at 3-month follow-
up after the first HIFU session (median 4.70 mL, range
0.88–8.02 mL, p = 0.005 compared with the initial value).
After the second HIFU session, the significant volume
reduction continued until the 24-month visit (median
0.21 mL, range 0.09–1.66 mL, p = 0.003 compared with
the initial value) (Fig. 4). Reduction of FA treated with
two HIFU sessions is demonstrated in Fig. 5.
The percentage of volume reduction was comparable
between both groups until 6-month follow-up after the
first HIFU (mean 58.04 ± 16.9% in group 1 and 50.44 ±
Table 1 Baseline features of breast fibroadenomas treated with 1 session (group 1) or with 2 sessions (group 2) of HIFU
Group 1 Group 2 P value
(n = 19) (n = 7)
Age (years), mean ± SD 29.4 ± 10.8 26.6 ± 9.2 0.549a
BMI (kg/m2), mean ± SD 20.5 ± 3.4 20.0 ± 2.1 0.693a
Side, n (%)
left 6 (31.6) 3 (42.9) 0.945b
right 13 (68.4) 4 (57.1)
Quadrant, n (%)
up-out 8 (42.1) 2 (28.6) 0.454b
up-in 6 (31.6) 3 (42.9)
low-in 3 (15.8) 0 (0.0)
low-out 2 (10.5) 2 (28.6)
Depth (mm), mean ± SD 15.3 ± 3.9 15.9 ± 3.6 0.710a
Basal volume (mL), median (range) 1.82 (0.35–5.95) 8.14 (1.53–10.39) 0.0140c
Color flow Doppler pattern (%)
0 8 (42.1) 2 (28.5) 0.194b
I 8 (42.1) 1 (14.3)
II 2 (10.5) 3 (42.9)
III 1 (5.3) 1(14.3)
aStudent’s t-test, bChi-square-test, cMann-Whitney U test
Table 2 Treatment characteristics at each HIFU session
Group 1 (n = 19) Group 2 (n = 7)
1st HIFU 1st HIFU 2nd HIFU
Treated volume (mL), median (range) 0.78 (0.35–2.24)a 2.66 (0.52–3.01) 1.34 (0.65–2.24)
Treated volume (%), mean ± SD 56.96 ± 25.05 36.02 ± 7.92b 58.50 ± 22.34
Total delivered energy (kJ), median (range) 10.1 (4.4–25.4)c 27.7 (7.4–39.6) 16.5 (12.8–31.4)
Energy per treated volume (kJ/mL), median, range 12.4 (6.7–14.3) 13.0 (10.4–14.2) 13.9 (7.1–14.8)
Treatment duration (min) mean ± SD 60.6 ± 22.8d 105.1 ± 38.8 66.3 ± 15.7
Number of treated sites, median (range) 58 (29–149)e 179 (38–221) 95 (40–153)
Hyperechoic marks (%), median (range) 15 (0–31) 10 (0–29) 7 (0–50)
ap < 0.05 compared with group 2 at the 1st HIFU and group 2 at the 2nd HIFU, Mann-Whitney U test, bp < 0.05 compared with group 1 and group 2 at the 2nd HIFU,
Student’s t-test, cp < 0.01 compared with group 2 at the 1st HIFU and group 2 at the 2nd HIFU, Mann-Whitney U test, dp < 0.001 compared with group 2 at the 1st
HIFU, Student’s t-test, ep < 0.05 compared with group 2 at the 1st HIFU, Mann-Whitney U test
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Fig. 2 Fibroadenoma volume reduction in patients treated with one HIFU session. *p < 0.001 compared with the initial value before treatment
(repeated measures analysis of variance test)
Fig. 3 Radial scan of left breast fibroadenoma in 27-years old woman treated with one HIFU session. a baseline US shows an oval-shaped hypoechoic
well-defined lesion of 1.87 ml of volume; b 6 months after the treatment 64.6% of volume reduction was found; c at 12-month follow-up the volume
reduction was 73%; d the tendency continued up to 24 months with 78.6% of total volume reduction
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Fig. 4 Fibroadenoma volume reduction in patients treated with two HIFU sessions. *p < 0.01 compared with the initial value before treatment
(repeated measures analysis of variance test)
Fig. 5 Anti-radial scan of right breast fibroadenoma in 39-years old woman treated with two HIFU sessions. a baseline US shows an oval-shaped
hypoechoic well-defined lesion with volume of 10.87 ml; b 6 months after the first HIFU ablation 58.2% of volume reduction was observed, but
the FA was still large (4.35 ml); c 6 months after the second HIFU ablation the volume reduction was 96.5% from baseline; d the reduction progressed
at 12 months up to 98.7%; e at 24-month follow-up the total volume reduction was 99.1%
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10.38% in group 2, respectively). However, at 12-month
visit after the final treatment the percentage of volume
reduction was significantly higher in group 2 that re-
ceived two treatments (mean 71.02 ± 10.39% in group 1
compared with 86.28 ± 7.64% in group 2, p = 0.002).
Similar difference was found at 24-month visit (mean
77.32 ± 13.47% in group 1 compared with 90.47 ± 7.13%
in group 2, p = 0.025), when the maximal volume reduc-
tion in group 1 and 2 reached 94.67% and 99.13%, re-
spectively. During 24-month follow-up no case of
regrowth was observed.
In order to estimate the effects of HIFU on FA shrinkage,
we further compared the reduction of individual diameters
at 6-month follow-up after the first HIFU. In all FA, the
percentages of d1, d2 and d3 reduction were comparable
(mean 26.44% ± 12.64%, 25.92 ± 11.44%, 19.99 ± 24.22%,
respectively). After HIFU therapy, color Doppler flow
decreased or totally disappeared. We found a significant
positive correlation of initial CFD pattern with FA volume
reduction at 12 months (r = 0.450, p = 0.021).
Safety, tolerability and satisfaction of patients
HIFU was well tolerated by all patients and no serious
adverse events were observed. The VAS score at the first
HIFU session (mean 40.7 ± 24.6, range 5–78) did not differ
significantly from the VAS score at the second session
(mean 34.9 ± 17.9, range 7–64). There was no significant
correlation between the VAS score and age, BMI, FA
depth, total applied energy as well as the applied energy
per volume, initial FA volume or the duration of treat-
ment. Up to one week after the first treatment, 9/20
patients (45.0%) reported about mild to moderate
pain or tenderness of the treated FA, and similar sen-
sation was reported in 4/7 (57.1%) patients after the
second session. No patient needed additional analgesic
drugs after the therapy.
During the first HIFU treatment, 4 patients developed
mild subcutaneous oedema that disappeared at 1 week
without therapy. Immediately after the treatment, mild
to moderate erythema was detected in 3 patients treated
twice. In 2 of them, this reaction disappeared up to
1 week after each HIFU session. Only in one patient
with BMI 17.4 kg/m2 it evoluted as first-degree skin
burn with crusts and hyperpigmentation visible up to 6-
month follow-up. All side effects were transient and
showed complete resolution.
Patients' satisfaction
All patients completed a questionnaire. The level of sat-
isfaction with symptom disappearance was high (grade
3) in 50%, 45% were satisfied completely (grade 4),
whereas in 1 patient (5%) the level of satisfaction was
low (grade 2). With respect to cosmetic results, 19 out
of 20 patients (95%) were satisfied completely (grade 4)
and in 1 patient (5%) the level of satisfaction was high.
Discussion
Our single-center study demonstrates that US-guided
HIFU treatment is effective in treating breast FA as indi-
cated by a significant and stable volume reduction at
two years follow-up, when the mean reduction was
77.32% after one HIFU session and 90.47% after two
HIFU sessions. The procedure is safe, with favourable
cosmetic outcome and patient’s satisfaction.
The significant reduction of FA volume as a result of
US-guided HIFU is consistent with a report based on
multicentre study, where 72.5% FA volume reduction
was shown at 1-year follow-up [23]. A favourable treat-
ment effect of HIFU was previously described in patients
with breast cancer, in whom coagulation necrosis has
been obtained in 78% to 100% of treated breast tumour
volume [26, 27]. Based on our data, HIFU ablation re-
sults in substantial FA volume reduction 1 month after
therapy, and the volume continues to regress during the
long-term follow-up. According to this stable tendency,
further reduction may be expected. Besides, our data
show that with second treatment the volume reduction
can be additionally enhanced.
Feasibility and efficacy of HIFU performed under MR
guidance were first demonstrated in breast FA more
than a decade ago [21]. Compared with MR guidance,
US-guided FA treatment is faster, more comfortable for
the patient and it does not need contrast agent applica-
tion [28]. Besides, it enables real-time visualization of
the targeted volume as well as apparent grayscale
changes during the treatment for monitoring the re-
sponse to HIFU, demonstrated also in other treatment
indications [20, 29].
Currently, the accepted definitive treatment of FA is
breast-conserving surgery which removes the FA entirely
with a subsequent tissue volume defect and risk of com-
plications as bleeding, seroma formation and chronic in-
cisional pain [30]. The minimally invasive US-guided
vacuum-assisted percutaneous excision has better cos-
metic results but incomplete removal with 3.4% to 30%
rate of residual tumour associated with initial tumour
size over 20 mm [13, 31]. HIFU as an ablative treatment
modality competes with up-to-date established ablation
methods such as radiofrequency, laser or cryoablation.
However, the US-guided HIFU is entirely non-invasive,
without need of probe or antenna insertion in the FA. It
requires less recovery time and cost, and is associated
with only minor adverse events and with no complica-
tions as hematoma, infection or scar formation [21, 26].
It can be performed in case of multiple lesions, in one
or both breasts. During the long-term follow-up of our
patients, the residual lesions did not demonstrate a
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potential for regrowth, which cannot be stated for still
viable residual tissue after vacuum-assisted percutaneous
excision [31]. When the results are not satisfactory after
one treatment or the FA is still large, second HIFU is a
good option as shown in our study.
An important drawback of the HIFU treatment is the
long duration, which increases with the size of treated
FA. Another limitation is one layer treatment, which
may result in incomplete ablation. However, the later
presumption is not supported by our observation of pro-
portionate reduction of all three FA diameters, but larger
studies are needed to evaluate the exact mechanism of
FA shrinkage after ablation. Besides, an appropriate pa-
tient selection is needed in order to assure the accessi-
bility of the targeted FA. Whereas deeply situated lesion
may not be accessible to US beam, the superficial FA
localization associated with scarcity of subcutaneous fat
may result in skin burn as observed in one of our pa-
tients with low BMI. Certainly, the main limitation of
the study is the small number of observed patients, espe-
cially in the group treated with two sessions, which is
mainly due to the recent introduction of the method
and lack of previous experience.
Conclusions
Our results of US-guided HIFU ablation of breast FA pro-
vide evidence that the method is promising, efficient and
safe. Although one treatment session results in marked re-
duction of FA volume, the second treatment significantly
increases the degree of volume reduction. Due to its non-
invasive nature, the method is well tolerated and associ-
ated with high level of patients’ satisfaction. Therefore,
US-guided HIFU may become an alternative to other
well-established treatment modalities of breast FA. How-
ever, larger cohorts of patients with similar or even longer
follow-up should be evaluated in order to define the treat-
ment success.
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